Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00WDY
|
|||
| Former ID |
DIB007364
|
|||
| Drug Name |
BMS-903452
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 1 | [1] | |
| Company |
Bristol-Myers Squibb Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H19Cl2FN4O4S
|
|||
| Canonical SMILES |
CS(=O)(=O)C1=CC(=C(C=C1)N2C=C(C(=CC2=O)OC3CCN(CC3)C4=NC=C(C=N4)Cl)Cl)F
|
|||
| InChI |
1S/C21H19Cl2FN4O4S/c1-33(30,31)15-2-3-18(17(24)8-15)28-12-16(23)19(9-20(28)29)32-14-4-6-27(7-5-14)21-25-10-13(22)11-26-21/h2-3,8-12,14H,4-7H2,1H3
|
|||
| InChIKey |
OGIAVRWXUPYGGC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1339944-47-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucose-dependent insulinotropic receptor (GPR119) | Target Info | Modulator | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Insulin secretion | ||||
| WikiPathways | Incretin Synthesis, Secretion, and Inactivation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01240980) Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B). U.S. National Institutes of Health. | |||
| REF 2 | Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119. J MedChem. 2014 Sep 25;57(18):7499-508. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.